Vivacelle Bio, Inc.
Vivacelle Bio is a late-stage biopharma company focused on developing life-saving treatments for shock and trauma, utilizing patented phospholipid nanoparticle technology. Their pipeline includes VBI-S, a Phase 3-ready asset for septic shock, and VBI-1, a candidate for hemorrhagic shock, with ongoing clinical trials and a strong patent portfolio. The company aims to address unmet medical needs in critical illnesses caused by shock and trauma, with support from government agencies and venture capital.
Industries
Nr. of Employees
small (1-50)
Vivacelle Bio, Inc.
Chicago, Illinois, United States, North America
Products
Phase 3-ready phospholipid nanoparticle intravenous cardiovascular support fluid (lead clinical asset)
An intravenously administered, volume-expanding colloid composed of phospholipid nanoparticles formulated to absorb and redistribute nitric oxide/nitrite to reverse hypotension and improve organ perfusion in patients with septic-shock-associated hypovolemia.
Phase 2-ready refined phospholipid nanoparticle perfusion fluid for hemorrhagic shock
A refined version of the phospholipid nanoparticle fluid formulated for treatment of hemorrhagic shock and mitigation of reperfusion injury, developed for progression into mid-stage clinical evaluation.
Phase 3-ready phospholipid nanoparticle intravenous cardiovascular support fluid (lead clinical asset)
An intravenously administered, volume-expanding colloid composed of phospholipid nanoparticles formulated to absorb and redistribute nitric oxide/nitrite to reverse hypotension and improve organ perfusion in patients with septic-shock-associated hypovolemia.
Phase 2-ready refined phospholipid nanoparticle perfusion fluid for hemorrhagic shock
A refined version of the phospholipid nanoparticle fluid formulated for treatment of hemorrhagic shock and mitigation of reperfusion injury, developed for progression into mid-stage clinical evaluation.
Services
Licensing and co-development partnerships
Negotiation and collaboration for out-licensing, co-development, global strategic development, and commercialization of nanoparticle-based critical care therapeutics.
Licensing and co-development partnerships
Negotiation and collaboration for out-licensing, co-development, global strategic development, and commercialization of nanoparticle-based critical care therapeutics.
Expertise Areas
- Clinical trial management in critical care (Phase II–III)
- Nanoparticle formulation and colloid engineering
- Shock and trauma therapeutics development
- Mechanism-of-action and translational research
Key Technologies
- Phospholipid nanoparticle formulations
- Micellar colloids / lipid bilayer and micelle systems
- Intravenous volume-expanding colloidal fluids
- Nitric oxide / nitrite absorption and redistribution mechanism